ABBV vs BEAT

AbbVie (ABBV) remains a well-established mega-cap pharmaceutical company, demonstrating stable, incremental growth driven by its robust immunology portfolio, notably Skyrizi and Rinvoq. Q1 2026 results showed modest revenue and adjusted EPS growth, with slightly raised full-year guidance. While financially healthy and a strong dividend payer, its immense market capitalization ($381.10B) and the ma...

Heartbeam continues to possess intriguing long-term potential anchored by its innovative 3D VECG technology and FDA-cleared AIMIGo, targeting a critical and expanding cardiovascular monitoring market. The leadership has demonstrated relevant expertise and achieved regulatory milestones. However, the company's financial state remains extremely precarious with $0 revenue in Q1 2026, a substantial ne...